Investigational Drug Information for SAGE-217
✉ Email this page to a colleague
What is the drug development status for SAGE-217?
SAGE-217 is an investigational drug.
There have been 14 clinical trials for SAGE-217.
The most recent clinical trial was a Phase 3 trial, which was initiated on December 1st 2016.
The most common disease conditions in clinical trials are Depressive Disorder, Depression, and Depressive Disorder, Major. The leading clinical trial sponsors are Sage Therapeutics and [disabled in preview].
There are five US patents protecting this investigational drug and one hundred and twenty-four international patents.
Summary for SAGE-217
| US Patents | 5 |
| International Patents | 124 |
| US Patent Applications | 42 |
| WIPO Patent Applications | 24 |
| Japanese Patent Applications | 3 |
| Clinical Trial Progress | Phase 3 (2016-12-01) |
| Vendors | 28 |
Recent Clinical Trials for SAGE-217
| Title | Sponsor | Phase |
|---|---|---|
| SAGE-217 Pharmacokinetics (PK) and Safety Study Pediatric Participants With Major Depressive Disorder (MDD) | Sage Therapeutics | Phase 1 |
| A Comparative Study of Sage-217 Plus an Antidepressant (ADT) Versus Placebo Plus an ADT in Adults With Major Depressive Disorder | Sage Therapeutics | Phase 3 |
| A Study to Evaluate the Efficacy and Safety of SAGE-217 in Participants With Severe Postpartum Depression (PPD) | Sage Therapeutics | Phase 3 |
Clinical Trial Summary for SAGE-217
Top disease conditions for SAGE-217
Top clinical trial sponsors for SAGE-217
US Patents for SAGE-217
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| SAGE-217 | ⤷ Sign Up | 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof | Sage Therapeutics, Inc. | ⤷ Sign Up |
| SAGE-217 | ⤷ Sign Up | 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof | Sage Therapeutics, Inc. | ⤷ Sign Up |
| SAGE-217 | ⤷ Sign Up | Neuroactive steroids, compositions, and uses thereof | Sage Therapeutics, Inc. (Cambridge, MA) | ⤷ Sign Up |
| SAGE-217 | ⤷ Sign Up | Crystalline 19-nor C3,3-disubstituted C21-N-pyrazolyl steroid | Sage Therapeutics, Inc. | ⤷ Sign Up |
| SAGE-217 | ⤷ Sign Up | 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof | SAGE THERAPEUTICS, INC. | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for SAGE-217
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| SAGE-217 | Australia | AU2014256229 | 2033-04-17 | ⤷ Sign Up |
| SAGE-217 | Australia | AU2018278844 | 2033-04-17 | ⤷ Sign Up |
| SAGE-217 | Australia | AU2020256400 | 2033-04-17 | ⤷ Sign Up |
| SAGE-217 | Australia | AU2022205157 | 2033-04-17 | ⤷ Sign Up |
| SAGE-217 | Brazil | BR112015026380 | 2033-04-17 | ⤷ Sign Up |
| SAGE-217 | Canada | CA2909545 | 2033-04-17 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
